A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, and Immunogenicity of Chimpanzee Adenovirus Type 3- Vectored Zaire Ebolavirus (ChAd3-EBO-Z) and Modified Vaccinia Ankara- Vectored Multivalent Filovirus (MVA-BN(R)-Filo) Vaccine Candidates
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2019
At a glance
- Drugs GSK 3390107A (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine
- Indications Ebola virus infections
- Focus Adverse reactions; Proof of concept
- 25 Oct 2018 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 Planned initiation date changed from 11 Oct 2018 to 1 Nov 2018.
- 20 Sep 2018 Planned initiation date changed from 20 Sep 2018 to 11 Oct 2018.